Karen E Knudsen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3018657/publications.pdf

Version: 2024-02-01

157 papers	15,919 citations	13827 67 h-index	17546 121 g-index
160 all docs	160 docs citations	160 times ranked	21086 citing authors

#	Article	IF	Citations
1	Relevance of pRB Loss in Human Malignancies. Clinical Cancer Research, 2022, 28, 255-264.	3.2	15
2	Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer. Cancer Research, 2022, 82, 221-234.	0.4	6
3	Mutant p53 elicits context-dependent pro-tumorigenic phenotypes. Oncogene, 2022, 41, 444-458.	2.6	13
4	A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2022, 28, 1446-1459.	3.2	12
5	Assessing the Coverage of US Cancer Center Primary Catchment Areas. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 955-964.	1.1	8
6	DNA-PKcs: A Targetable Protumorigenic Protein Kinase. Cancer Research, 2022, 82, 523-533.	0.4	21
7	Optimizing the Use of Telemedicine in Oncology Care: Postpandemic Opportunities. Clinical Cancer Research, 2021, 27, 933-936.	3.2	42
8	Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discovery, 2021, 11, 1118-1137.	7.7	124
9	Differential expression of Î±VÎ²3 and Î±VÎ²6 integrins in prostate cancer progression. PLoS ONE, 2021, 16, e0244985.	1.1	16
10	The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair. Nature Communications, 2021, 12, 401.	5.8	60
11	Prostate cancer. Nature Reviews Disease Primers, 2021, 7, 9.	18.1	434
12	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. Clinical Cancer Research, 2021, 27, 3017-3027.	3.2	19
13	RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease. Cancer Discovery, 2021, 11, 2334-2353.	7.7	40
14	The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology. Journal of Personalized Medicine, 2021, 11, 330.	1.1	1
15	The SAGA complex regulates early steps in transcription via its deubiquitylase module subunit USP22. EMBO Journal, 2021, 40, e102509.	3.5	9
16	Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness. Urologic Clinics of North America, 2021, 48, 339-347.	0.8	5
17	Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multiâ€phased study of prostate cancer. Cancer Communications, 2021, 41, 1387-1397.	3.7	6
18	Decreased local immune response and retained HPV gene expression during chemoradiotherapy are associated with treatment resistance and death from cervical cancer. International Journal of Cancer, 2020, 146, 2047-2058.	2.3	26

#	Article	IF	Citations
19	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	9.4	198
20	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	0.8	170
21	Cellular rewiring in lethal prostate cancer: the architect of drug resistance. Nature Reviews Urology, 2020, 17, 292-307.	1.9	59
22	Double Trouble: Concomitant RB1 and BRCA2 Depletion Evokes Aggressive Phenotypes. Clinical Cancer Research, 2020, 26, 1784-1786.	3.2	3
23	USP22 Functions as an Oncogenic Driver in Prostate Cancer by Regulating Cell Proliferation and DNA Repair. Cancer Research, 2020, 80, 430-443.	0.4	46
24	Cancer and the Circadian Clock. Cancer Research, 2019, 79, 3806-3814.	0.4	140
25	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clinical Cancer Research, 2019, 25, 6916-6924.	3.2	200
26	Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies. Clinical Cancer Research, 2019, 25, 5623-5637.	3.2	23
27	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. Clinical Cancer Research, 2019, 25, 5608-5622.	3.2	17
28	SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Science Advances, 2019, 5, eaax6352.	4.7	31
29	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clinical Cancer Research, 2019, 25, 4290-4299.	3.2	38
30	Expanding Role of Germline DNA Repair Alterations in Prostate Cancer Risk and Early Onset. European Urology, 2019, 76, 338-339.	0.9	1
31	Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. Prostate, 2019, 79, 333-339.	1.2	69
32	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. International Journal of Cancer, 2019, 144, 1151-1159.	2.3	13
33	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 687-697.	3.2	43
34	DNA Damage Response in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a030486.	2.9	40
35	Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle. Molecular Pharmaceutics, 2018, 15, 1778-1790.	2.3	3
36	Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 1402-1414.	3.2	34

#	Article	IF	Citations
37	Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas <i>In Vivo</i> and <i>Ex Vivo</i>. Molecular Cancer Therapeutics, 2018, 17, 84-95.	1.9	22
38	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	0.8	155
39	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. Journal of Clinical Oncology, 2018, 36, 991-999.	0.8	169
40	PARPâ€1 regulates DNA repair factor availability. EMBO Molecular Medicine, 2018, 10, .	3.3	52
41	Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9298-E9307.	3.3	91
42	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	13.5	459
43	MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer. Clinical Cancer Research, 2018, 24, 4201-4214.	3.2	77
44	A patientâ€derived explant (<scp>PDE</scp>) model of hormoneâ€dependent cancer. Molecular Oncology, 2018, 12, 1608-1622.	2.1	94
45	Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. Cell, 2018, 174, 1200-1215.e20.	13.5	96
46	Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. European Urology Oncology, 2018, 1, 325-337.	2.6	37
47	Splice Variants and Phosphorylated Isoforms of Cyclin D1 in Tumorigenesis. Current Cancer Research, 2018, , 91-109.	0.2	0
48	Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer. Cancer Research, 2017, 77, 2439-2452.	0.4	32
49	Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle. Cancer Cell, 2017, 31, 471-473.	7.7	8
50	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discovery, 2017, 7, 999-1005.	7.7	223
51	PARP Inhibitors in Prostate Cancer. Current Treatment Options in Oncology, 2017, 18, 37.	1.3	50
52	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Reports, 2017, 19, 2045-2059.	2.9	99
53	RB Loss Promotes Prostate Cancer Metastasis. Cancer Research, 2017, 77, 982-995.	0.4	67
54	Posttranscriptional Regulation of <i>PARG</i> mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors. Cancer Research, 2017, 77, 5011-5025.	0.4	59

#	Article	IF	Citations
55	Detection of Activating Estrogen Receptor Gene (<i>ESR1</i>) Mutations in Single Circulating Tumor Cells. Clinical Cancer Research, 2017, 23, 6086-6093.	3.2	68
56	Cell cycle-coupled expansion of AR activity promotes cancer progression. Oncogene, 2017, 36, 1655-1668.	2.6	32
57	Differential impact of RB status on E2F1 reprogramming in human cancer. Journal of Clinical Investigation, 2017, 128, 341-358.	3.9	83
58	Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urology Case Reports, 2016, 9, 51-54.	0.1	0
59	There and Back Again: The Middle Earth of DNA Repair. Molecular Cancer Research, 2016, 14, 895-897.	1.5	1
60	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncology, 2016, 2, 471.	3.4	46
61	Linking DNA Damage and Hormone Signaling Pathways in Cancer. Trends in Endocrinology and Metabolism, 2016, 27, 216-225.	3.1	52
62	Consequence of the tumorâ€associated conversion to cyclin D1b. EMBO Molecular Medicine, 2015, 7, 628-647.	3.3	19
63	Models of neuroendocrine prostate cancer. Endocrine-Related Cancer, 2015, 22, R33-R49.	1.6	45
64	Cell-cycle-dependent regulation of androgen receptor function. Endocrine-Related Cancer, 2015, 22, 249-264.	1.6	30
65	DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Cancer Cell, 2015, 28, 97-113.	7.7	148
66	Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors. Neoplasia, 2015, 17, 385-399.	2.3	212
67	Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. Molecular Cell, 2015, 58, 925-934.	4.5	114
68	Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1106-15.	3.3	376
69	Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer. Clinical Cancer Research, 2015, 21, 795-807.	3.2	89
70	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 2015, 373, 1697-1708.	13.9	1,796
71	Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. Molecular Cancer Research, 2015, 13, 1591-1601.	1.5	41
72	The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc. Neoplasia, 2014, 16, 900-908.	2.3	216

#	Article	IF	Citations
73	Hormone Whodunit: Clues for Solving the Case of Intratumor Androgen Production. Clinical Cancer Research, 2014, 20, 5343-5345.	3.2	3
74	USP22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer Progression. Cancer Research, 2014, 74, 272-286.	0.4	98
75	Transcriptional Roles of PARP1 in Cancer. Molecular Cancer Research, 2014, 12, 1069-1080.	1.5	144
76	AR function in promoting metastatic prostate cancer. Cancer and Metastasis Reviews, 2014, 33, 399-411.	2.7	73
77	Targeting PARP-1 Allosteric Regulation Offers Therapeutic Potential against Cancer. Cancer Research, 2014, 74, 31-37.	0.4	47
78	<i>PCAT-1</i>, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer. Cancer Research, 2014, 74, 1651-1660.	0.4	237
79	AMP ed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy. EMBO Molecular Medicine, 2014, 6, 439-441.	3.3	5
80	Beyond DNA Repair: DNA-PK Function in Cancer. Cancer Discovery, 2014, 4, 1126-1139.	7.7	202
81	Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1038-1046.	0.4	149
82	The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness. Clinical Cancer Research, 2014, 20, 5468-5482.	3.2	19
83	Progesterone Receptorâ€"Cyclin D1 Complexes Induce Cell Cycleâ€"Dependent Transcriptional Programs in Breast Cancer Cells. Molecular Endocrinology, 2014, 28, 442-457.	3.7	36
84	Fusing Transcriptomics to Progressive Prostate Cancer. American Journal of Pathology, 2014, 184, 2608-2610.	1.9	0
85	Targeted Radiosensitization of ETS Fusion-Positive Prostate Cancer through PARP1 Inhibition. Neoplasia, 2013, 15, 1207-IN36.	2.3	49
86	Molecular Pathogenesis and Progression of Prostate Cancer. Seminars in Oncology, 2013, 40, 244-258.	0.8	96
87	The Epigenetic Modifier Ubiquitin-specific Protease 22 (USP22) Regulates Embryonic Stem Cell Differentiation via Transcriptional Repression of Sex-determining Region Y-box 2 (SOX2). Journal of Biological Chemistry, 2013, 288, 24234-24246.	1.6	74
88	Ex vivo culture of human prostate tissue and drug development. Nature Reviews Urology, 2013, 10, 483-487.	1.9	111
89	Beyond the Cell Cycle: Implications of D-type Cyclin Deregulation in Prostate Cancer. , 2013, , 461-477.		0
90	IGF2 revs the steroidogenesis engine. Endocrine-Related Cancer, 2013, 20, C19-C21.	1.6	1

#	Article	IF	Citations
91	Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes. Clinical Cancer Research, 2013, 19, 2657-2667.	3.2	32
92	A Hormoneâ€"DNA Repair Circuit Governs the Response to Genotoxic Insult. Cancer Discovery, 2013, 3, 1254-1271.	7.7	294
93	Targeting cell cycle and hormone receptor pathways in cancer. Oncogene, 2013, 32, 5481-5491.	2.6	98
94	Middlegame Theory, Cancer Style: A Message from the Editor-in-Chief. Molecular Cancer Research, 2013, 11, 3-4.	1.5	0
95	Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. Journal of Clinical Investigation, 2013, 123, 493-508.	3.9	38
96	The Role of Tumor Suppressor Dysregulation in Prostate Cancer Progression. Current Drug Targets, 2013, 14, 460-471.	1.0	16
97	mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocrine-Related Cancer, 2012, 19, 1-12.	1.6	48
98	Targeting Pioneering Factor and Hormone Receptor Cooperative Pathways to Suppress Tumor Progression. Cancer Research, 2012, 72, 1248-1259.	0.4	35
99	Cyclin D1 goes metabolic. Cell Cycle, 2012, 11, 3534-3534.	1.3	6
100	Dual Roles of PARP-1 Promote Cancer Growth and Progression. Cancer Discovery, 2012, 2, 1134-1149.	7.7	354
101	Evidence for Efficacy of New Hsp90 Inhibitors Revealed by <i>Ex Vivo</i> Culture of Human Prostate Tumors. Clinical Cancer Research, 2012, 18, 3562-3570.	3.2	92
102	The AR dependent cell cycle: Mechanisms and cancer relevance. Molecular and Cellular Endocrinology, 2012, 352, 34-45.	1.6	45
103	Abstract IA9: Cross talk of the androgen receptor and DNA damage pathways: Molecular and translational prostate cancer relevance. Cancer Research, 2012, 72, IA9-IA9.	0.4	0
104	FOXA1: master of steroid receptor function in cancer. EMBO Journal, 2011, 30, 3885-3894.	3.5	162
105	Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. International Journal of Biochemistry and Cell Biology, 2011, 43, 1318-1329.	1.2	16
106	Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Review of Endocrinology and Metabolism, 2011, 6, 483-493.	1.2	48
107	Postprostatectomy radiation therapy: an evidence-based review. Future Oncology, 2011, 7, 1429-1440.	1.1	12
108	Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocrine-Related Cancer, 2011, 18, 333-345.	1.6	256

#	Article	IF	Citations
109	A tale of three PKCs. Cell Cycle, 2011, 10, 379-379.	1.3	1
110	The meaning of p16^{ink4a}expression in tumors. Cell Cycle, 2011, 10, 2497-2503.	1.3	240
111	Cyclin D1 Is a Selective Modifier of Androgen-dependent Signaling and Androgen Receptor Function*. Journal of Biological Chemistry, 2011, 286, 8117-8127.	1.6	37
112	Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nature Reviews Urology, 2011, 8, 562-568.	1.9	39
113	Nuclear Targeting of Cyclin-Dependent Kinase 2 Reveals Essential Roles of Cyclin-Dependent Kinase 2 Localization and Cyclin E in Vitamin D-Mediated Growth Inhibition. Endocrinology, 2010, 151, 896-908.	1.4	54
114	Identification of ASF/SF2 as a Critical, Allele-Specific Effector of the Cyclin D1b Oncogene. Cancer Research, 2010, 70, 3975-3984.	0.4	71
115	Alternative Splicing of the Cyclin D1 Proto-Oncogene Is Regulated by the RNA-Binding Protein Sam68. Cancer Research, 2010, 70, 229-239.	0.4	157
116	RB-pathway disruption in breast cancer. Cell Cycle, 2010, 9, 4153-4163.	1.3	163
117	Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends in Endocrinology and Metabolism, 2010, 21, 315-324.	3.1	248
118	The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. Journal of Clinical Investigation, 2010, 120, 4478-4492.	3.9	268
119	Functional Specificities of Brm and Brg-1 Swi/Snf ATPases in the Feedback Regulation of Hepatic Bile Acid Biosynthesis. Molecular and Cellular Biology, 2009, 29, 6170-6181.	1.1	38
120	Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer. Clinical Cancer Research, 2009, 15, 4792-4798.	3.2	275
121	Hijacking the Chromatin Remodeling Machinery: Impact of<i>SWI/SNF</i>Perturbations in Cancer. Cancer Research, 2009, 69, 8223-8230.	0.4	102
122	Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer. Clinical Cancer Research, 2009, 15, 5338-5349.	3.2	84
123	Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer. Oncogene, 2009, 28, 1016-1027.	2.6	22
124	Tailoring to RB: tumour suppressor status and therapeutic response. Nature Reviews Cancer, 2008, 8, 714-724.	12.8	311
125	2,2-Bis(4-Chlorophenyl)-1,1-Dichloroethylene Stimulates Androgen Independence in Prostate Cancer Cells through Combinatorial Activation of Mutant Androgen Receptor and Mitogen-Activated Protein Kinase Pathways. Molecular Cancer Research, 2008, 6, 1507-1520.	1.5	14
126	The SWI/SNF ATPase Brm Is a Gatekeeper of Proliferative Control in Prostate Cancer. Cancer Research, 2008, 68, 10154-10162.	0.4	71

#	Article	IF	Citations
127	Targeting the BAF57 SWI/SNF Subunit in Prostate Cancer: A Novel Platform to Control Androgen Receptor Activity. Cancer Research, 2008, 68, 4551-4558.	0.4	71
128	Cyclin D1b Is Aberrantly Regulated in Response to Therapeutic Challenge and Promotes Resistance to Estrogen Antagonists. Cancer Research, 2008, 68, 5628-5638.	0.4	65
129	AR, the cell cycle, and prostate cancer. Nuclear Receptor Signaling, 2008, 6, nrs.06001.	1.0	300
130	Androgen-mediated Control of the Cyclin D1-RB Axis: Implications for Prostate Cancer. Research and Perspectives in Endocrine Interactions, 2008, , 63-81.	0.2	1
131	Retinoblastoma Tumor Suppressor Status Is a Critical Determinant of Therapeutic Response in Prostate Cancer Cells. Cancer Research, 2007, 67, 6192-6203.	0.4	77
132	The Complex Role of AR Signaling After Cytotoxic Insult: Implications for Cell Cycle Based Chemotherapeutics. Cell Cycle, 2007, 6, 1307-1313.	1.3	32
133	Unique Bisphenol A Transcriptome in Prostate Cancer: Novel Effects on ERÎ² Expression That Correspond to Androgen Receptor Mutation Status. Environmental Health Perspectives, 2007, 115, 1646-1653.	2.8	36
134	An evaluation of evidence for the carcinogenic activity of bisphenol A. Reproductive Toxicology, 2007, 24, 240-252.	1.3	249
135	The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. Journal of Clinical Investigation, 2007, 117, 218-228.	3.9	178
136	Retinoblastoma Tumor Suppressor: Where Cancer Meets the Cell Cycle. Experimental Biology and Medicine, 2006, 231, 1271-1281.	1.1	85
137	The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Division, 2006, 1, 15.	1.1	62
138	Mitogenic Action of the Androgen Receptor Sensitizes Prostate Cancer Cells to Taxane-Based Cytotoxic Insult. Cancer Research, 2006, 66, 11998-12008.	0.4	21
139	Androgen receptor corepressors and prostate cancer. Endocrine-Related Cancer, 2006, 13, 979-994.	1.6	67
140	Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Molecular Cancer Therapeutics, 2006, 5, 3181-3190.	1.9	72
141	Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2190-2195.	3.3	123
142	A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene, 2005, 24, 431-444.	2.6	63
143	BAF57 Governs Androgen Receptor Action and Androgen-Dependent Proliferation through SWI/SNF. Molecular and Cellular Biology, 2005, 25, 2200-2215.	1.1	117
144	Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Research, 2005, 65, 54-65.	0.4	67

#	Article	IF	Citations
145	2,3,7,8-Tetrachlorodibenzo-p-dioxin Blocks Androgen-Dependent Cell Proliferation of LNCaP Cells through Modulation of pRB Phosphorylation. Molecular Pharmacology, 2004, 66, 502-511.	1.0	85
146	Differential Requirement of SWI/SNF for Androgen Receptor Activity. Journal of Biological Chemistry, 2003, 278, 30605-30613.	1.6	93
147	Specificity of cyclin D1 for androgen receptor regulation. Cancer Research, 2003, 63, 4903-13.	0.4	63
148	Compensation of BRG-1 Function by Brm. Journal of Biological Chemistry, 2002, 277, 4782-4789.	1.6	97
149	Cyclin D1: Mechanism and Consequence of Androgen Receptor Co-repressor Activity. Journal of Biological Chemistry, 2002, 277, 2207-2215.	1.6	128
150	Androgen Mediated Regulation of the G1-S Transition in Prostate Cancer. , 2002, , 91-110.		2
151	The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Molecular Cancer Therapeutics, 2002, 1, 515-24.	1.9	130
152	Retinoblastoma Tumor Suppressor Protein Signals through Inhibition of Cyclin-Dependent Kinase 2 Activity To Disrupt PCNA Function in S Phase. Molecular and Cellular Biology, 2001, 21, 4032-4045.	1.1	53
153	RB-Dependent S-Phase Response to DNA Damage. Molecular and Cellular Biology, 2000, 20, 7751-7763.	1.1	213
154	The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene, 1999, 18, 5239-5245.	2.6	57
155	Cyclin A Is a Functional Target of Retinoblastoma Tumor Suppressor Protein-mediated Cell Cycle Arrest. Journal of Biological Chemistry, 1999, 274, 27632-27641.	1.6	66
156	Hus1p, a conserved fission yeast checkpoint protein, interacts with Rad1p and is phosphorylated in response to DNA damage. EMBO Journal, 1998, 17, 2055-2066.	3.5	110
157	Multiple G1 Regulatory Elements Control the Androgen-dependent Proliferation of Prostatic Carcinoma Cells. Journal of Biological Chemistry, 1998, 273, 20213-20222.	1.6	165